Anal canal carcinoma is relevant because it commonly occurs in high-risk groups, and its incidence has been increasing.
This study evaluated the accuracy of anal cytology in the screening of precursor lesions of anal cancer, compared with histopathologic examination as the reference, in all subjects and in men who have sex with men, HIV-infected men and women, and men who have sex with men and HIV-infected subgroups.
The data included studies identified in the MEDLINE, Latin American and Caribbean Health Sciences, Cochrane Library, and Embase electronic databases, as well as in the grey literature. The search terms included anal cancer, anal dysplasia, anal intraepithelial neoplasia, screening, and anal cytology.
After excluding studies with no histopathological data and those with duplicate and missing data, 34 primary studies were included.
Cytology of anal smears was studied.
Sensitivity, specificity, diagnostic OR, and area under the curve were measured.
A total of 5093 patients were included. The pooled sensitivity of anal cytology was 85.0% (95% CI, 82.0%–87.0%) and pooled specificity was 43.2% (95% CI, 41.4%–45.1%) for the detection of anal intraepithelial neoplasia grade 2 or worse versus anal intraepithelial neoplasia grade 1 and normal when measuring all subjects. The accuracy of anal cytology was higher in the men who have sex with men and HIV-infected and men who have sex with men only subgroups.
This study was limited by its specificity.
The study results support the hypothesis that cytology is a good test for the screening of anal cancer.
1 Translational Biomedicine Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina, Criciúma, Santa Catarina, Brazil
2 Department of Medicine, Centro Universitário do Espírito Santo, University of Southern Santa Catarina, Colatina, Espírito Santo, Brazil
3 Laboratory of Evidence in Health, Medicine and Health Sciences, University of State of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
Funding/Support: None reported.
Financial Disclosure: None reported.
Correspondence: Maria Inês da Rosa, Ph.D., Translational Biomedicine Laboratory, Graduate Program in Health Sciences, University of Southern Santa Catarina, Criciúma, SC, Brazil 88806000. E-mail: email@example.com